Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) on April 13, 2018. The registrant is an emerging growth company incorporated in Delaware. The report details the pricing of a public offering of common stock, Series C Convertible Preferred Stock, and warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $11.25 million expected from the offering.
- Net Proceeds: Approximately $10.1 million expected after deducting placement agent fees, expenses, and estimated offering costs.
- Offering Price: Combined purchase price of $0.32 per share of common stock (or equivalent) and warrant.
- Securities Issued: Up to 14,730,000 shares of common stock, 6,536.4 shares of Series C Convertible Preferred Stock, and warrants exercisable for up to 35,156,250 shares of common stock.
- Placement Agent Fees: 7.0% cash placement fee, 0.5% management fee, $25,000 expense allowance, and up to $100,000 for legal fee reimbursement.
Material Changes
The filing reports a material definitive agreement entered into on April 13, 2018, regarding the public offering. The filing text does not provide comparative financial data (revenue, profit, cash flow, or margins) for prior periods as this is a current report on a specific transaction rather than a periodic financial statement.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Net proceeds will support operations, clinical trials, working capital, and general corporate purposes. This may include research and development efforts and potential acquisitions or in-licensing of products, though none are currently contemplated.
- Preferred Stock Terms: The Series C Convertible Preferred Stock is convertible into common stock at $0.32 per share. It has no voting rights or dividend preferences over common stock except in limited circumstances. Conversion is subject to a 4.99% beneficial ownership limitation (increasable to 9.99%).
- Warrant Terms: Warrants are immediately exercisable, expire in five years, and have an exercise price of $0.32. They are subject to a 4.99% beneficial ownership limitation (increasable to 9.99% with notice).
- Closing Date: The offering is expected to close on April 17, 2018.
Investor Verification Checklist
- Verify the final closing date and actual gross/net proceeds received on or after April 17, 2018.
- Review the Certificate of Designation (Exhibit 3.1) for specific rights and limitations of the Series C Convertible Preferred Stock.
- Confirm the exact number of shares issued and the final exercise price of warrants in the post-closing filings.
- Monitor future filings for updates on the utilization of proceeds for clinical trials or potential acquisitions.
- Check for any subsequent amendments to the beneficial ownership limitations on the Preferred Stock and warrants.